Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
38 results about "BTLA" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
B- and T-lymphocyte attenuator is a protein that in humans is encoded by the BTLA gene. BTLA has also been designated as CD272 (cluster of differentiation 272).
BTLA nucleic acids
InactiveUS7304149B2Decrease autoreactive lymphocyte activityEnhanced signalCell receptors/surface-antigens/surface-determinantsSugar derivativesLymphocyteInhibitory receptors
The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies B7 family member B7x as interacting with BTLA to attenuate lymphocyte activity. Methods and compositions for modulating BTLA-mediated negative signaling and interfering with the interaction of BTLA and B7x for therapeutic, diagnostic and research purposes are also provided.
Owner:WASHINGTON UNIV IN SAINT LOUIS
CD86 Antagonist Multi-Target Binding Proteins
This disclosure provides a multi-specific fusion protein composed of a CD86 antagonist binding domain and another binding domain that is an IL-10 agonist, an HLA-G agonist, an HGF agonist, an IL-35 agonist, a PD-1 agonist, a BTLA agonist, a LIGHT antagonist, a GITRL antagonist or a CD40 antagonist. The multi-specific fusion protein may also include an intervening domain that separates the other domains. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions.
Owner:APTEVO RES & DEV LLC
Compositions and methods for modulating lymphocyte activity
The invention derives from the identification of HVEM as the native ligand for BTLA. The invention provides compositions and methods for modulating BTLA-HVEM interactions and BTLA and HVEM activity, which are useful for modulating immune responses. Agonists and antagonists of the BTLA-HVEM interaction are provided, and methods of treating a variety of conditions through the modulation of immune responses are provided.
Owner:WASHINGTON UNIV IN SAINT LOUIS
Method for assessing a prognosis and predicting the response of patients with malignant diseases to immunotherapy
The invention relates to, among others, a method for assessing a prognosis of a patient with a malignant disease and / or for predicting the response of a patient with a malignant disease to immunotherapy. For this purpose, a DNA methylation analysis is carried out on at least one immunoregulatory gene of cells of the malignant disease and / or T lymphocytes which interact with the cells of the malignant disease, said gene coding for an immune checkpoint selected from B7 proteins and the receptors thereof, MHC-peptide complex-binding co-receptors, the members of the tumor necrosis factor receptorsuperfamily TNFRSF9, CD40, TNFRSF4, TNFRSF18, and CD27, the members of the immunoglobulin superfamily TIGIT, BTLA, HAVCR2, BTNL2, and CD48, and the andenosine-binding adenosine 2A receptor.
Owner:迪莫迪特里希
Fully human antibodies to btla
ActiveUS20120183565A1High binding affinityNeutralizing activitySenses disorderBacteriaDiseaseAntiendomysial antibodies
Owner:MEDAREX LLC
Human monoclonal antibodies to BTLA and methods of use
ActiveUS8580259B2Enhances and stimulates and increases immune responseReduces and suppresses immune responseAntibacterial agentsAntimycoticsInfective disorderMonoclonal
The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to BTLA with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for detecting BTLA, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-BTLA antibodies.
Owner:ER SQUIBB & SONS INC
Methods of modulating hvem, btla and cd160 cis complex response or signaling activity with soluble light polypeptide sequences
InactiveUS20100129389A1Inhibits and prevents spontaneous multimerizationInhibition of activationNervous disorderAntibody mimetics/scaffoldsAntibodyChemistry
The invention provides HVEM cis complexes which include, for example, HVEM / BTLA, HVEM / CD160 and HVEM / gD cis complexes. The invention provides ligands and agents that bind to HVEM cis complexes, such as antibodies. The invention further provides methods of use of the HVEM cis complexes, and the ligands and agents (e.g., LIGHT polypeptide sequence) that bind to the HVEM cis complexes.
Owner:LA JOLLA INST FOR ALLERGY & IMMUNOLOGY
B and T lymphocyte attenuator marker for use in adoptive T-cell therapy
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Human monoclonal antibodies to btla and methods of use
ActiveUS20120288500A1Enhances and stimulates and increases immune responseReduces and suppresses immune responseAntibacterial agentsAntimycoticsInfective disorderMonoclonal
The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to BTLA with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for detecting BTLA, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-BTLA antibodies.
Owner:MEDAREX LLC
Preparation method and application of humanized gene modified animal model
The invention relates to a gene modified non-human animal of a humanized gene, especially a gene modified rodent animal and in especially a gene modified mouse, and in particular relates to a construction method of the humanized BTLA gene animal model, a subsequently generated animal and an application of the animal model in the field of bio-medicine.
Owner:BIOCYTOGEN JIANGSU CO LTD +1
CD86 antagonist multi-target binding proteins
This disclosure provides a multi-specific fusion protein composed of a CD86 antagonist binding domain and another binding domain that is an IL-10 agonist, an HLA-G agonist, an HGF agonist, an IL-35 agonist, a PD-1 agonist, a BTLA agonist, a LIGHT antagonist, a GITRL antagonist or a CD40 antagonist. The multi-specific fusion protein may also include an intervening domain that separates the other domains. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions.
Owner:APTEVO RES & DEV LLC
BTLA Antibodies and Uses Thereof
InactiveUS20150147344A1Animal cellsImmunoglobulins against cell receptors/antigens/surface-determinantsAntibodyAntiendomysial antibodies
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2
Compositions and methods for modulating lymphocyte activity
InactiveUS20120207759A1Antibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsLymphocyteInhibitory receptors
The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies HVEM as interacting with BTLA. Methods and compositions for modulating BTLA-mediated signaling and interfering with the interaction of BTLA and HVEM for therapeutic, diagnostic and research purposes are also provided.
Owner:WASHINGTON UNIV IN SAINT LOUIS
Hvem/btla, hvem/cd 160 and hvem/gd cis complexes and methods of use
The invention provides HVEM cis complexes which include, for example, HVEM / BTLA, HVEM / CD160 and HVEM / gD cis complexes. The invention provides ligands and agents that bind to HVEM cis complexes, such as antibodies. The invention further provides methods of use of the HVEM cis complexes, and the ligands and agents (e.g., antibodies) that bind to the HVEM cis complexes.
Owner:LA JOLLA INST FOR ALLERGY & IMMUNOLOGY
Compositions and methods for modulating lymphocyte activity
InactiveUS20120322986A1Antibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsLymphocyteInhibitory receptors
Owner:WASHINGTON UNIV IN SAINT LOUIS
Compositions and methods for modulating lymphocte activity
InactiveUS20080269464A1Negatively regulatesInhibitory activityCell receptors/surface-antigens/surface-determinantsAntibody mimetics/scaffoldsLymphocyteInhibitory receptors
The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies B7 family member B7x as interacting with BTLA to attenuate lymphocyte activity. Methods and compositions for modulating BTLA-mediated negative signaling and interfering with the interaction of BTLA and B7x for therapeutic, diagnostic and research purposes are also provided.
Owner:WASHINGTON UNIV IN SAINT LOUIS
Compositions and methods for modulating lymphocyte activity
InactiveUS20120214972A1Negatively regulatesInhibitory activityCell receptors/surface-antigens/surface-determinantsAntibody mimetics/scaffoldsLymphocyteInhibitory receptors
The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies B7 family member B7x as interacting with BTLA to attenuate lymphocyte activity. Methods and compositions for modulating BTLA-mediated negative signaling and interfering with the interaction of BTLA and B7x for therapeutic, diagnostic and research purposes are also provided.
Owner:WASHINGTON UNIV IN SAINT LOUIS
Antagonist of the btla/hvem interaction for use in therapy
InactiveUS20160122434A1Increased proliferationFast penetrationNervous disorderAntipyreticCancer researchAntagonist
Owner:INST JEAN PAOLI & IRENE CALMETTES +3
BTLA fusion protein agonists and uses thereof
Owner:SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST +1
Group of markers for predicting storm of immune checkpoint of COVID-19, application and kit thereof
PendingCN112255410AQuick checkAccurate detectionDisease diagnosisBiological testingCD80Biomarker (medicine)
The invention provides a group of markers for predicting the storm of an immune checkpoint of COVID-19, application, a kit and a preparation method of the kit, which belong to the technical field of biological medicines. The markers provided by the invention comprise one or more than two of BTLA, GITR, HVEM, IDO, LAG-3, PD-1, PD-L1, TIM-3, CD28, CD80, 4-1BB, CD27 and CD152. When the biomarker or the kit prepared from the biomarker provided by the invention is used for predicting the storm of the immune checkpoint of the COVID-19, the biomarker or the kit has the advantages of rapidness and accuracy in detection, low cost and the like, and has a wide application prospect.
Owner:BEIJING IMMUPEUTICS MEDICINE TECH LTD
Preparing method and application of BTLA<-/->T lymphocytes resistant to tumor immunosuppression environment
InactiveCN109136190AAttack ability activatedTo achieve the purpose of treatmentStable introduction of DNAPeptidesAbnormal tissue growthSerum free media
The invention discloses a preparing method of BTLA<- / ->T lymphocytes resistant to the tumor immunosuppression environment. The preparing method includes the steps that T lymphocytes are obtained through separation from peripheral blood of a tumor patient, BTLA is subjected to gene knockout in vitro with the CRISPR-Cas9 technology, then the obtained T lymphocytes are put into a serum-free medium and cultured, IFN-gamma, a CD3 monoclonal antibody, IL-2, IL-1alpha, IL-4, GM-CSF and Puromycin are added, the obtained T lymphocytes continue to be cultured for 10 days to 15 days, then centrifugationis carried out, and the BTLA<- / ->T lymphocytes are obtained. The preparing method of the BTLA<- / ->T lymphocytes is ingenious in design, the BTLA<- / ->T lymphocytes prepared with the method have the characteristic resistant to the tumor immunosuppression environment, and have the better tumor killing effect, the clinical effect is improved, and a novel anti-tumor and tumor treatment mean is provided.
Owner:北京中诚华科生物科技有限公司
Anti-BTLA antibody pharmaceutical composition and application thereof
The invention provides a pharmaceutical composition of a stable anti-BTLA (B and T lymphocyte attenuator) antibody and an application of the pharmaceutical composition in medicine. The pharmaceutical composition contains an anti-BTLA antibody and a buffer solution, can also contain at least one stabilizer, and can also optionally contain a surfactant.
Owner:SHANGHAI JUNSHI BIOSCI +1
Therapeutic combination and method for treating cancer
PendingUS20220089753A1Efficient responseGood curative effectOrganic active ingredientsPeptide/protein ingredientsAntiendomysial antibodiesImmunotherapeutic agent
Owner:TCM BIOTECH INT CORP
BTLA-binding antibodies for modulating immune response and treating disease
ActiveUS11384146B2Nervous disorderImmunoglobulins against cell receptors/antigens/surface-determinantsAutoimmune conditionAntiendomysial antibodies
The invention provides novel anti-BTLA antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer or autoimmune disease.
Owner:CURIA IP HLDG LLC +1
Lrfft2 cell
ActiveUS20200102537A1Precise killing abilityIncrease lethalityImmunoglobulin superfamilyHydrolasesAntigen epitopeDendritic cell
Some embodiments of the disclosure use human peripheral blood for ctDNA sequencing or tumor tissues for whole exome sequencing, screen out mutation sites to perform antigen epitope prediction, connect and synthesize an expression gene sequence of mutant peptides. Other embodiments of the disclosure construct a lentiviral vector, package the lentivirus, transfect an APC cell to complete transformation of a specific LV cell, co-culture in vitro with PBMC separated from the peripheral blood, screen out an effective polypeptide, and transform common T cells into RFF cells. Suppressive signaling molecules include one or more of PD-1, Tim-3, LAG3, CTLA-4, BTLA, VISTA, CD160, and 2B4 (CD244). Antigen presenting cells include one or more of PBMC, a dendritic cell, neutrophil, B lymphocyte, and macrophage.
Owner:BEIJING DCTY BIOTECH CO LTD +1
Btla fusion protein agonists and uses thereof
The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind BTLA enhancing BTLA signaling The present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a BTLA agonist fusion protein as described herein.
Owner:SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST +1
Pluripotent stem cell for expressing shRNA and/or shRNA-miR of targeted BTLA or derivative of pluripotent stem cell
PendingCN114657137ABlock BTLA pathwayRelief of immunosuppressionOrganic active ingredientsPeptide/protein ingredientsAntigenBiochemistry
Owner:FUTURE HOMO SAPIENS INST OF REGENERATIVE MEDICINE CO LTD (FHSR) +1
Anti-hvem antibodies and use thereof
PendingCN114026124AImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsDiseaseAntiendomysial antibodies
Owner:4C BIOMED LTD +1
Btla antibodies
PendingCN113454119AHigh binding affinityHigh agonist potencyAntipyreticDigestive systemDiseaseAntigen Binding Fragment
The invention relates generally to antibodies or antigen binding fragments that bind to human B and T lymphocyte attenuator (BTLA) and uses thereof. More specifically, the invention relates to agonistic antibodies that bind human BTLA and modulate its activity, and their use in treating inflammatory, autoimmune and proliferative diseases and disorders.
Owner:OXFORD UNIV INNOVATION LTD +1
Btla-binding antibodies for modulating immune response and treating disease
ActiveUS20200325230A1Stimulate immune responseSuppress immune responseNervous disorderImmunoglobulins against cell receptors/antigens/surface-determinantsAutoimmune conditionAntiendomysial antibodies
The invention provides novel anti-BTLA antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer or autoimmune disease.
Owner:CURIA IP HLDG LLC +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com